These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 16041948)

  • 21. ENHANCE: food for the ostriches.
    Jackson G
    Int J Clin Pract; 2008 May; 62(5):667-8. PubMed ID: 18412925
    [No Abstract]   [Full Text] [Related]  

  • 22. Tolerability and effects on lipids of ezetimibe coadministered with pravastatin or simvastatin for twelve months: results from two open-label extension studies in hypercholesterolemic patients.
    Strony J; Hoffman R; Hanson M; Veltri E
    Clin Ther; 2008 Dec; 30(12):2280-97. PubMed ID: 19167588
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biomarkers and surrogate endpoints in cardiovascular therapeutics research: under scrutiny following results of the ENHANCE Study.
    Pauriah M; Struthers AD; Lang CC
    Cardiovasc Ther; 2008; 26(2):85-8. PubMed ID: 18485130
    [No Abstract]   [Full Text] [Related]  

  • 24. [Lowering LDL cholesterol frequently does not adhere to guidelines. Also regard intestinal cholesterol source].
    MMW Fortschr Med; 2005 Jun; 147(23):48-9. PubMed ID: 15981908
    [No Abstract]   [Full Text] [Related]  

  • 25. Simvastatin with or without ezetimibe in familial hypercholesterolemia.
    Eichhorn EJ
    N Engl J Med; 2008 Jul; 359(5):529-30; author reply 532. PubMed ID: 18677795
    [No Abstract]   [Full Text] [Related]  

  • 26. Simvastatin with or without ezetimibe in familial hypercholesterolemia.
    Connor WE
    N Engl J Med; 2008 Jul; 359(5):530; author reply 532-3. PubMed ID: 18677797
    [No Abstract]   [Full Text] [Related]  

  • 27. [Dual lipid control without anti-atherosclerosis effect].
    Einecke D
    MMW Fortschr Med; 2008 Apr; 150(16):18, 20. PubMed ID: 18557109
    [No Abstract]   [Full Text] [Related]  

  • 28. [Preventing infarct by lowering LDL. Is 100 the upper limit for every diabetic patient?].
    MMW Fortschr Med; 2003 Sep; 145(38):60. PubMed ID: 14603687
    [No Abstract]   [Full Text] [Related]  

  • 29. [Hypercholesterolemia: when statins are not enough or not tolerated. With combination therapy to LDL cholesterol target goal].
    MMW Fortschr Med; 2012 Jul; 154(13):86-7. PubMed ID: 22957390
    [No Abstract]   [Full Text] [Related]  

  • 30. Understanding practice patterns and low-density lipoprotein cholesterol goal attainment implications of switching patients from simvastatin in a health plan setting.
    Harley CR; Gandhi SK; Anoka N; Bullano MF; McKenney JM
    Am J Manag Care; 2007 Dec; 13 Suppl 10():S276-81. PubMed ID: 18095778
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients.
    Catapano AL; Davidson MH; Ballantyne CM; Brady WE; Gazzara RA; Tomassini JE; Tershakovec AM
    Curr Med Res Opin; 2006 Oct; 22(10):2041-53. PubMed ID: 17022864
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.
    Guyton JR; Brown BG; Fazio S; Polis A; Tomassini JE; Tershakovec AM
    J Am Coll Cardiol; 2008 Apr; 51(16):1564-72. PubMed ID: 18420099
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction.
    Robinson JG; Davidson MH
    Expert Rev Cardiovasc Ther; 2006 Jul; 4(4):461-76. PubMed ID: 16918265
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effects of low-dose simvastatin and ezetimibe compared to high-dose simvastatin alone on post-fat load endothelial function in patients with metabolic syndrome: a randomized double-blind crossover trial.
    Olijhoek JK; Hajer GR; van der Graaf Y; Dallinga-Thie GM; Visseren FL
    J Cardiovasc Pharmacol; 2008 Aug; 52(2):145-50. PubMed ID: 18670365
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is there a problem with ezetimibe or just ENHANCEd hype?
    Whayne TF
    Angiology; 2008 Dec-2009 Jan; 59(6):661-3. PubMed ID: 18796445
    [No Abstract]   [Full Text] [Related]  

  • 36. [Statins plus inhibition of cholesterol absorption. Dual mechanism of action in lipid therapy].
    MMW Fortschr Med; 2002 Sep; 144(35-36):51. PubMed ID: 12380358
    [No Abstract]   [Full Text] [Related]  

  • 37. After the failure of ENHANCEd cholesterol lowering in familial hypercholesterolemia, SEAS of problems with ezetimibe.
    Mascitelli L; Ravnskov U; Pezzetta F; Goldstein MR
    Angiology; 2009; 60(1):127-8; author reply 129-30. PubMed ID: 19049996
    [No Abstract]   [Full Text] [Related]  

  • 38. Lipid-lowering effects of colesevelam HCl in combination with ezetimibe.
    Bays H; Rhyne J; Abby S; Lai YL; Jones M
    Curr Med Res Opin; 2006 Nov; 22(11):2191-200. PubMed ID: 17076980
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Hydroxymethylglutaryl coenzyme A reductase inhibitors].
    Schuff-Werner P
    Internist (Berl); 1994 Mar; 35(3):288-94; discussion 295. PubMed ID: 8175295
    [No Abstract]   [Full Text] [Related]  

  • 40. Combination of simvastatin with berberine improves the lipid-lowering efficacy.
    Kong WJ; Wei J; Zuo ZY; Wang YM; Song DQ; You XF; Zhao LX; Pan HN; Jiang JD
    Metabolism; 2008 Aug; 57(8):1029-37. PubMed ID: 18640378
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.